RecruitingPhase 2NCT06584006

Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors

A Phase II, Single-Center, Randomized Controlled Clinical Trial Evaluating the Efficacy of Thymalfasin and Recombinant Human Interleukin-2 Injections in Treating Lymphocytopenia in Patients With Malignant Hematological Tumors

Sponsor

The First Affiliated Hospital of Xiamen University

Enrollment

50 participants

Start Date

Sep 1, 2024

Study Type

INTERVENTIONAL

Conditions

Hematological Malignancy Lymphocytopenia

Summary

To evaluate the efficacy and safety of Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections in the treatment of lymphocytopenia in patients with malignant hematological tumors

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Recombinant Human Interleukin-2 Injections and a drug called Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections for people with hematological malignancy and lymphocytopenia. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGThymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections

Thymalfasin for injection 1.6mg subcutaneous injection once daily (qd) for 7 days, and Recombinant Human Interleukin-2 Injections 1 million units subcutaneous injection qd for 7 days.

DRUGRecombinant Human Interleukin-2 Injections

Recombinant Human Interleukin-2 Injections 1 million units subcutaneous injection qd for 7 days.

Locations(1)

Zhijuan Lin

Xiamen, Fujian, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06584006

Related Trials

Study to Evaluate the Safety and Effectiveness of Withaferin A as a Treatment to Prevent GvHD in Transplant Patients

NCT077248732 locations

Study of Standardized Withaferin-A for the Treatment of Steroid Refractory Acute Graft Versus Host Disease.

NCT077089871 location

Halt Aging in Survivors of Blood Cancers

NCT072922721 location

Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia

NCT055378961 location

HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib

NCT038503661 location